BACKGROUND: The majority of breast cancer patients in Mexico are treated through the public health system and >80% receive adjuvant chemotherapy. The aim of this prospective study was to characterize the impact of the Oncotype DX assay on adjuvant therapy decision making and the confidence in those decisions amongst public sector physicians in Mexico. METHODS: Ninety-eight consecutive patients with ER+, HER2-, stage I-IIIa, N0/N1-3 node-positive breast cancer from the Instituto Nacional de Cancerología were eligible for the study. The primary endpoint was the overall change in treatment recommendations after receiving the assay results. RESULTS: Of 96 patients, 48% received a chemohormonal therapy recommendation prior to testing. Following receipt of results, treatment decisions changed for 31/96 (32%) patients, including 17/62 (27%) node-negative patients and 14/34 (41%) node-positive patients. The proportion of patients with a chemotherapy-based recommendation decreased from 48% pre- to 34% post-assay (P=0.024). 92% of physicians agreed that they were more confident in their treatment recommendation after ordering the assay. CONCLUSIONS: These results suggest that use of the 21-gene assay in the Mexican public health system has a meaningful impact on adjuvant treatment recommendations that may reduce the overall use of chemotherapy.
BACKGROUND: The majority of breast cancerpatients in Mexico are treated through the public health system and >80% receive adjuvant chemotherapy. The aim of this prospective study was to characterize the impact of the Oncotype DX assay on adjuvant therapy decision making and the confidence in those decisions amongst public sector physicians in Mexico. METHODS: Ninety-eight consecutive patients with ER+, HER2-, stage I-IIIa, N0/N1-3 node-positive breast cancer from the Instituto Nacional de Cancerología were eligible for the study. The primary endpoint was the overall change in treatment recommendations after receiving the assay results. RESULTS: Of 96 patients, 48% received a chemohormonal therapy recommendation prior to testing. Following receipt of results, treatment decisions changed for 31/96 (32%) patients, including 17/62 (27%) node-negative patients and 14/34 (41%) node-positive patients. The proportion of patients with a chemotherapy-based recommendation decreased from 48% pre- to 34% post-assay (P=0.024). 92% of physicians agreed that they were more confident in their treatment recommendation after ordering the assay. CONCLUSIONS: These results suggest that use of the 21-gene assay in the Mexican public health system has a meaningful impact on adjuvant treatment recommendations that may reduce the overall use of chemotherapy.
Authors: K Willemsma; W Yip; N LeVasseur; K Dobosz; C Illmann; S Baxter; C Lohrisch; C E Simmons Journal: Curr Oncol Date: 2020-05-01 Impact factor: 3.677
Authors: Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil Journal: Cancer Control Date: 2016-10 Impact factor: 3.302
Authors: G Thomas Ray; Jeanne Mandelblatt; Laurel A Habel; Scott Ramsey; Lawrence H Kushi; Yan Li; Tracy A Lieu Journal: Am J Manag Care Date: 2016-05-01 Impact factor: 2.229
Authors: Cynthia Villarreal-Garza; Edna Anakarenn Lopez-Martinez; Zuratzi Deneken-Hernandez; Antonio Maffuz-Aziz; Jose Felipe Muñoz-Lozano; Regina Barragan-Carrillo; Pier Ramos-Elias; Brizio Moreno; Hector Diaz-Perez; Omar Peña-Curiel; Jose de Jesus Curiel-Valdez; Veronica Bautista-Piña Journal: PLoS One Date: 2020-03-11 Impact factor: 3.240
Authors: Nicholas Acuna; Jesse J Plascak; Jennifer Tsui; Antoinette M Stroup; Adana A M Llanos Journal: Int J Environ Res Public Health Date: 2021-05-12 Impact factor: 3.390